Comparative Pharmacology
Head-to-head clinical analysis: ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER versus TAZICEF.
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic